afami-cel,nivolumab,adp-a2m4cd8
adaptimmune therapeutics,bms
['a2m4cd8', 'solid tumor', 'adp-a2m4', 'surpass']
it was lovely speaking to ( ) who took us through surpass, the phase i trial of adp-a2m4cd8, a next-generation autologous t-cell receptor t-cell therapy in solid tumors #esmo22 #cart 
The Video Journal of Oncology is dedicated to providing trusted information to improve knowledge, understanding and awareness of cancer. Intended for HCPs only.